

Antonello Veccia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6608837/antonello-veccia-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

118
citations

6
h-index

10
g-index

17
ext. papers

154
ext. citations

4.1
avg, IF

2.34
L-index

#	Paper	IF	Citations
15	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. <i>Joint Bone Spine</i> , 2022 , 105403	2.9	
14	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 162, 103351	7	8
13	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 389-400	3.5	0
12	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. <i>Future Oncology</i> , 2021 , 17, 597-609	3.6	1
11	Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. <i>Immunotherapy</i> , 2021 , 13, 1093-1103	3.8	0
10	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020 , 140, 140-146	7.5	12
9	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019 , 15, 1115-1123	3.6	5
8	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018 , 14, 431-442	3.6	10
7	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699	3.6	2
6	Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?. <i>Nature Reviews Urology</i> , 2017 , 14, 1	5.5	6
5	Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung cancer treatment. <i>Journal of B U on</i> , 2017 , 22, 1395-1403		
4	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
3	Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016 , 12, 333-42	3.6	22
2	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 498-506	7	40
1	Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study. <i>Radiation Oncology</i> , 2015 , 10, 130	4.2	5